8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 17, 2026·SEC
Galectin Therapeutics Inc.(GALT)Earnings, Financials & Key Ratios
GALT•NASDAQ
$4.23
Price updated Jun 25, 2026
AboutGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Show more
- Revenue$0
- EBITDA-$20M+52.8%
- Net Income-$31M+34.5%
- EPS (Diluted)-0.48+36.8%
GALT Price & Volume
Galectin Therapeutics Inc. (GALT) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Capital Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial outcome
"Galectin Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on the binary success of its NAVIGATE Phase III clinical trial. The company's reliance on debt-like financing and persistent equity dilution to fund operations creates a precarious financial profile for long-term investors. Future valuation is tethered exclusively to clinical outcomes, as the firm currently lacks any commercial revenue streams to offset its significant operating losses."
Verdict Logic
the company's cash position of $14.1 million as of 2026Q1 appears insufficient to sustain the current burn rate, signaling a high probability of further dilutive financing.
GALT Growth Metrics
Galectin Therapeutics Inc. (GALT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM41.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.47%
Return on Capital
10 Years-183.32%
5 Years-208.36%
3 Years-270.38%
Last Year-174.62%
GALT Recent Earnings
Galectin Therapeutics Inc. (GALT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.08-33.3%
$0.06
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.08+20.0%
$0.10
Rev
—
$36M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.08+20.0%
$0.10
Rev
—
$36M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.13-18.2%
$0.11
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.08vs $0.06-33.3% | — |
| Q2 2026 | Mar 31, 2026 | $0.08vs $0.10+20.0% | —vs $36M |
| Q2 2026 | Mar 30, 2026 | $0.08vs $0.10+20.0% | —vs $36M |
| Q4 2025 | Nov 14, 2025 | $0.13vs $0.11-18.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Galectin Therapeutics Inc. (GALT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.23 | $278.57M | -8.81 | — | — | — | — | |
| $72.64 | $8.62B | 28.37 | 37.55% | 23.13% | 126.27% | — | |
| $1.04 | $278.99M | -50.00 | 47.46% | -8.83% | -62.72% | — | |
| $513.79 | $11.85B | -39.98 | 432.05% | -27.32% | -50.15% | — | |
| $49.12 | $2.99B | -26.84 | — | — | -21.04% | — | |
| $34.99 | $3.69B | -7.07 | 640.71% | -2747.18% | -43.96% | — |
Compare GALT vs Peers
Galectin Therapeutics Inc. (GALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GALT SEC Filings & Documents
Galectin Therapeutics Inc. (GALT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GALT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GALT Frequently Asked Questions
Galectin Therapeutics Inc. (GALT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GALT profitable?
Galectin Therapeutics Inc. (GALT) reported a net loss of $26.3M for fiscal year 2025.
Dividend & Returns
What is Galectin Therapeutics Inc.'s free cash flow?
Galectin Therapeutics Inc. (GALT) had negative free cash flow of $20.1M in fiscal year 2025, likely due to heavy capital investments.